Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABP Abpro	$0.17 -19.5%	$0.33	$0.15 ▼ $13.00	$8.62M	-0.01	434,026 shs	5.47 million shs
CNTB Connect Biopharma	$0.77 +1.2%	$0.74	$0.51 ▼ $2.07	$42.62M	-0.3	55,822 shs	87,108 shs
KPTI Karyopharm Therapeutics	$4.85 -1.4%	$5.46	$3.51 ▼ $17.85	$41.56M	0.33	82,759 shs	71,800 shs
QNCX Quince Therapeutics	$0.84 -11.4%	$1.18	$0.51 ▼ $2.45	$37.13M	0.83	283,849 shs	478,293 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABP Abpro	-19.51%	-25.34%	-44.07%	-83.66%	+16,499,900.00%
CNTB Connect Biopharma	+1.18%	-3.75%	+18.30%	-21.35%	-60.31%
KPTI Karyopharm Therapeutics	-1.42%	-20.62%	+15.20%	-46.97%	-70.34%
QNCX Quince Therapeutics	-11.43%	-19.10%	-17.51%	-40.75%	-7.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABP Abpro	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	3.3262 of 5 stars	3.5	5.0	0.0	0.0	2.6	2.5	0.6
KPTI Karyopharm Therapeutics	3.7674 of 5 stars	3.5	0.0	0.0	4.6	2.3	2.5	0.6
QNCX Quince Therapeutics	2.8989 of 5 stars	3.6	3.0	0.0	0.0	2.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABP Abpro	3.00	Buy	$4.00	2,324.24% Upside
CNTB Connect Biopharma	3.00	Buy	$8.00	938.96% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	790.72% Upside
QNCX Quince Therapeutics	3.29	Buy	$8.00	850.80% Upside

Current Analyst Ratings Breakdown

Latest ABP, KPTI, CNTB, and QNCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
3/31/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/25/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $4.00
3/24/2025	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00
2/26/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $56.00
2/24/2025	ABP Abpro	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
2/20/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$45.00 ➝ $45.00
2/20/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $105.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABP Abpro	$183K	47.08	N/A	N/A	N/A	∞
CNTB Connect Biopharma	$26.03M	1.64	N/A	N/A	$1.83 per share	0.42
KPTI Karyopharm Therapeutics	$145.24M	0.29	N/A	N/A	($1.47) per share	-3.30
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$1.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABP Abpro	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	-$59.50M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	-$143.10M	-$15.29	N/A	N/A	N/A	-52.62%	N/A	-39.58%	N/A
QNCX Quince Therapeutics	-$31.39M	-$1.31	N/A	N/A	N/A	N/A	-53.27%	-22.73%	N/A

Latest ABP, KPTI, CNTB, and QNCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	QNCX Quince Therapeutics	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
3/24/2025	Q4 2024	QNCX Quince Therapeutics	-$0.19	-$0.28	-$0.09	-$0.28	N/A	$0.17 million
2/19/2025	Q4 2024	KPTI Karyopharm Therapeutics	-$3.90	-$3.60	+$0.30	-$0.24	$30.29 million	$30.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABP Abpro	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABP Abpro	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	12.04	N/A
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
QNCX Quince Therapeutics	0.33	9.53	9.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABP Abpro	23.30%
CNTB Connect Biopharma	58.72%
KPTI Karyopharm Therapeutics	66.44%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
ABP Abpro	19.80%
CNTB Connect Biopharma	22.60%
KPTI Karyopharm Therapeutics	2.98%
QNCX Quince Therapeutics	20.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABP Abpro	15	52.22 million	4.57 million	N/A
CNTB Connect Biopharma	110	55.35 million	42.77 million	Optionable
KPTI Karyopharm Therapeutics	380	8.57 million	122.72 million	Optionable
QNCX Quince Therapeutics	60	44.12 million	36.61 million	Optionable

ABP, KPTI, CNTB, and QNCX Headlines

Recent News About These Companies

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 14 at 3:19 AM | finance.yahoo.com

Quince Therapeutics (QNCX) to Release Quarterly Earnings on Monday

May 11, 2025 | americanbankingnews.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Average Price Target from Brokerages

May 10, 2025 | americanbankingnews.com

Quince Therapeutics to Present at Citizens Life Sciences Conference

April 30, 2025 | businesswire.com

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

April 3, 2025 | businesswire.com

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)

March 27, 2025 | markets.businessinsider.com

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

March 24, 2025 | businesswire.com

Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation

March 24, 2025 | msn.com

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

February 7, 2025 | businesswire.com

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025 | businesswire.com

Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia

February 4, 2025 | markets.businessinsider.com

Quince Therapeutics secures USPTO nod for A-T treatment patent

February 4, 2025 | msn.com

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

February 4, 2025 | businesswire.com

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

January 27, 2025 | finance.yahoo.com

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

January 24, 2025 | finance.yahoo.com

Quince Therapeutics initiated with a Buy at Brookline

December 19, 2024 | msn.com

Brookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation

December 19, 2024 | msn.com

Quince Therapeutics Share Price (QNCX.US)

November 18, 2024 | lse.co.uk

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

November 13, 2024 | businesswire.com

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

November 13, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP, KPTI, CNTB, and QNCX Company Descriptions

Abpro NASDAQ:ABP

$0.16 -0.04 (-19.51%)

As of 05/14/2025 04:00 PM Eastern

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Connect Biopharma NASDAQ:CNTB

$0.77 +0.01 (+1.18%)

As of 05/14/2025 03:49 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Karyopharm Therapeutics NASDAQ:KPTI

$4.85 -0.07 (-1.42%)

As of 05/14/2025 04:00 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Quince Therapeutics NASDAQ:QNCX

$0.84 -0.11 (-11.43%)

As of 05/14/2025 04:00 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time